Publications

Découvrez ci-dessous les publications scientifiques des dernières années.

  1. Hubert de Boysson H, Devauchelle-Pensec V, Agard C, André M, Bienvenu B, Bonnotte B, Carvajal Alegria G, Espitia O, Hachulla E, Heron E, Lambert M, Lega JC, Ly KH, Mekinian A, Morel J, Regent A, Richez C, Sailler L, Seror R, Tournadre A, Samson M; Collaborators. French protocol for the diagnosis and management of giant cell arteritis. Rev Med Interne. 2025 Jan;46(1):12-31. - DOI : 10.1016/j.revmed.2024.10.011
  2. Nowak S, Jaffuel D, Morel J, Ahmed E, Gamez AS, Boissin C, Charriot J, Molinari N, Bourdin A. Phenotypes and prognosis of systemic sclerosis: A cluster analysis. Respir Med Res. 2025 Mar 21;87:101168. - DOI : 10.1016/j.resmer.2025.101168

  1. Wendling D, Al Tabaa O, Chevet B, Fakih O, Ghossan R, Hecquet S, Dernis E, Maheu E, Saraux A, Besson FL, Alegria GC, Cortet B, Fautrel B, Felten R, Morel J, Ottaviani S, Querellou-Lefranc S, Ramon A, Ruyssen-Witrand A, Seror R, Tournadre A, Foulquier N, Verlhac B, Verhoeven F, Devauchelle-Pensec V. Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica. Joint Bone Spine. 2024;91(4):105730. - DOI : 10.1016/j.jbspin.2024.105730
  2. Kristensen LE, Ng KJ, Ngantcha M, Morel J, Lubrano E, Tillett W, Alten R, Chandran V, Martinez Ferrer À, Zhu B, Kennedy D, Holzkämper T, Gullick N, Kronbergs A, Fakhouri W, de la Torre I, McGonagle DG. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study. RMD Open. 2024 Sep 20;10(3):e004318. - DOI : 10.1136/rmdopen-2024-004318
  3. Nguyen Y, Nocturne G, Henry J, Ng WF, Belkhir R, Desmoulins F, Bergé E, Morel J, Perdriger A, Dernis E, Devauchelle-Pensec V, Sène D, Dieudé P, Couderc M, Fauchais AL, Larroche C, Vittecoq O, Salliot C, Hachulla E, Le Guern V, Gottenberg JE, Mariette X, Seror R. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts. Lancet Rheumatol. 2024 Apr;6(4):e216-e225. - DOI : 10.1016/S2665-9913(23)00340-5
  4. Mouterde G, Lukas C, Filippi N, Marin G, Molinari N, Combe B, Morel J. Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study. RMD Open. 2024 Sep 17;10(3):e004269. - DOI : 10.1136/rmdopen-2024-004269
  5. Nguyen Y, Mariette X, Gottenberg JE, Iudici M, Morel J, Vittecoq O, Constantin A, Flipo RM, Schaeverbeke T, Sibilia J, Ravaud P, Porcher R, Seror R. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry. Rheumatology (Oxford). 2024 Jul 1;63(7):1893-1901. - DOI : 10.1093/rheumatology/kead495
  6. Nguyen Y, Baron G, Hamamouche N, Belkhir R, Miconnet S, Soubrier M, Hostachy C, Thevenot P, Basch A, Truchetet ME, Claudepierre P, Dernis E, Marotte H, Flipo RM, Brocq O, Morel J, Fautrel B, Salliot C, Saraux A, Leske C, Schaeverbeke T, Ravaud P, Mariette X, Ruyssen-Witrand A, Seror R; ART study group. Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort. Rheumatology (Oxford). 2024 Nov 22:keae599. - DOI : 10.1093/rheumatology/keae599
  7. Immediato Daien C, Georgescu V, Decarriere G, Mercier G, Morel J. Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study. RMD Open. 2024 Oct 2;10(4):e004490. - DOI : 10.1136/rmdopen-2024-004490
  8. Tison A, Jousse-Joulin S, Consigny M, Moog P, Hofauer B, Hachulla E, Lamotte C, Morel J, Mouterde G, Milic V, Bootsma H, Stel A, Fisher BA, Maybury M, Baer A, DiRenzo D, Kim HR, Min HK, Lee SS, Choi SE, Alegria GC, Boisramé S, Guellec D, Cornec D, Quéré B, Jonsson M, Hammenfors D, Saraux A, Devauchelle-Pensec V. Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study. Rheumatology (Oxford). 2024 Dec 19:keae690. - DOI : 10.1093/rheumatology/keae690

  1. Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, Atzeni F, Behrens GM, Bijlsma JW, Böhm P, Constantinou CA, Garcia-Diaz S, Kapetanovic MC, Lauper K, Luís M, Morel J, Nagy G, Polverino E, van Rompay J, Sebastiani M, Strangfeld A, de Thurah A, Galloway J, Hyrich KL. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023 Jun;82(6):742-753. - DOI : 10.1136/ard-2022-223335
  2. Devauchelle-Pensec V, Mariette X, Benyoussef AA, Boisrame S, Cochener B, Cornec D, Nocturne G, Gottenberg JE, Hachulla E, Labalette P, Le Guern V, M'Bwang Seppoh R, Morel J, Orliaguet M, Saraux A, Seror R, Costedoat-Chalumeau N; Collaborators. French national diagnostic and care protocol for Sjögren's disease. Rev Med Interne. 2023 Aug;44(8):423-457. - DOI : 10.1016/j.revmed.2023.07.001
  3. Wetzman A, Lukas C, Gaujoux-Viala C, Mamtani R, Barnetche T, Combe B, Morel J, Szafors P. Arthritis Care Res (Hoboken). Risk of Cancer After Initiation of Targeted therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis. 2023 Feb;75(2):260-271. - DOI : 10.1002/acr.24784

  4. Rempenault C, Lukas C, Tardivon L, Daien C, Combe B, Guilpain P, and Morel J. Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease. 2024 Jan 30;10(1):e003415. - DOI : 10.1136/rmdopen-2023-003415

  5. Mouterde G et Morel J. Nouveautés dans l’imagerie du pied au cours de la polyarthrite rhumatoïde. Revue du rhumatisme (2023). - DOI : 10.1016/j.rhum.2023.11.006